Despite the success of prostate-specific antigen (PSA) as a tumor marker for the early detection and monitoring of disease in prostate cancer, both clinical and analytical limitations of PSA remain (1 ). Since the introduction of assays for total PSA in the mid-1980s, assay results have been found to differ among manufacturers (2, 3). Much has been learned in the last two decades about the biol...

PURPOSE Often, a diagnosis of pT3 is made on the basis of radical retropubic prostatectomy specimens, despite a Gleason score of 6 on the preoperative prostate biopsy. Thus, we investigated the preoperative variables in patients displaying these characteristics. MATERIALS AND METHODS Study subjects comprised patients at our institute from 1996 to July 2010 who had exhibited a Gleason score of...

Results: The analysis indicated that following five nodes had different levels of cancer possibility: (1) PSA > 5.98 ng/mL; (2) PSA ≤ 5.98 ng/mL and Digital Rectal Examination (DRE) is suspicious or positive; (3) PSA ≤5 .98 ng/mL and DRE is negative and free PSA > 0.81; (4) PSA ≤ 5.98 ng/mL and DRE is negative and free PSA ≤ 0.81 and age ≤ 57 years; (5) PSA ≤ 5.98 ng/mL and DRE is negative and ...

BACKGROUND Prostate-specific antigen (PSA) measurements in serum by immunoassay are widely used in the screening, diagnosis, and monitoring of patients with prostate cancer although the lack of common reference reagents has led in the past to wide differences in estimates. We report here the results of a WHO international collaborative study in which two preparations of PSA representative of th...

PURPOSE We determine whether biochemical prostate specific antigen (PSA) failure can be accurately predicted from preoperative serum PSA combined with 6 morphological variables from radical retropubic prostatectomy specimens in men with peripheral zone cancers. The unexpected limitation imposed by preoperative serum PSA on biochemical failure led us to compare peripheral zone to transition zone...

OBJECTIVES The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the specificity of total serum PSA for the detection of prostate carcinoma in selected populations. In this study, the value of the F/T ratio for screening of prostate cancer was compared with that of age-specific reference ranges for PSA and PSA density (PSAD) by a simulation e...

PURPOSE To evaluate prospectively the role of prostate-specific antigen (PSA) density in predicting Gleason score upgrading in prostate cancer patients eligible for active surveillance (T1/T2, biopsy Gleason score≤6, PSA≤10 ng/mL, and ≤2 positive biopsy cores). MATERIALS AND METHODS Between January 2010 and November 2013, among patients who underwent greater than 10-core transrectal ultrasoun...

BACKGROUND The proteome of the serine protease prostate-specific antigen (PSA) and its enzymatic properties have been clarified only recently. We have developed a specific and sensitive method for the measurement of active PSA and used it to measure proPSA in blood. METHODS We used the synthetic peptide KGISSQY, which possesses a PSA-specific cleavage site, as substrate. To ascertain the spec...